Alnylam Pharmaceuticals Forms Collaboration with Max Planck Institute of Molecular Cell Biology and Genetics Mechanisms for Cellular Uptake of RNAi Therapeutics

Published: Aug 11, 2008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced it has formed an exclusive research agreement with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, to investigate and characterize the molecular mechanisms underlying intracellular transport of small interfering RNA, (siRNA), the molecules that mediate RNAi.

Back to news